Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?

Executive Summary

Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.

Advertisement

Related Content

Marathon's High-Priced Window May Not Stay Open Long
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
Voucher Does Not Guarantee A Priority Review, FDA Says
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Priority Review Vouchers Appear To Be Dropping In Price
Priority Review Voucher Expansion Could Be Bad, Program Creator Says
Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances
PCSK9 Sponsors Looked For Regulatory Advantages In Race To Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel